Beijing, Sept 1, 2026 — China’s Center for Drug Evaluation (CDE) issued two technical guidelines for chemical generic drug eye drops, establishing research and development standards for standard and specialized ophthalmic formulations as regulators expand quality consistency evaluations beyond oral solids and injections.
Policy Snapshot
| Attribute | Detail |
|---|---|
| Issuer | Center for Drug Evaluation (CDE), National Medical Products Administration |
| Document | Technical Guidelines for Research on Chemical Generic Drug Eye Drops; Technical Guidelines for Research on Chemical Generic Drug Special Eye Drops |
| Announcement No. | 2026 No. 43 |
| Legal basis | State Council General Office Opinion on Deepening Drug and Medical Device Regulatory Reform (Guo Ban Fa [2024] No. 53) |
| Effective date | Sept 1, 2026 |
| Scope | Chemical generic drug eye drops (standard and specialized formulations) |
Key Provisions
The CDE released two complementary guidelines:
- Standard eye drops — The Technical Guidelines for Research on Chemical Generic Drug Eye Drops outlines requirements for formulation development, quality control, and bioequivalence assessment for conventional ophthalmic solutions and suspensions.
- Specialized eye drops — The Technical Guidelines for Research on Chemical Generic Drug Special Eye Drops addresses complex formulations including emulsions, gels, and sustained-release ophthalmic preparations, setting higher evidentiary bars for therapeutic equivalence.
Both documents align with the NMPA’s broader consistency evaluation framework and require marketing authorization holders to conduct comprehensive quality and efficacy studies referencing approved originator products.
Market Impact Analysis
The guidelines operationalize the NMPA’s Aug 2026 announcement expanding consistency evaluation to eye drops, giving manufacturers immediate technical direction for reformulation and registration. For domestic ophthalmic generics makers, the standards clarify previously ambiguous requirements around in vitro release testing, container closure integrity, and ocular tolerability studies—areas where Chinese generics have historically lagged global benchmarks.
The specialized eye drops guideline is particularly significant for complex formulations such as cyclosporine emulsions and prostaglandin analog suspensions, where therapeutic equivalence cannot be established through simple physicochemical matching. By mandating additional clinical endpoint or pharmacokinetic studies for these categories, regulators are raising the innovation threshold and potentially culling low-quality copycats from the market.
Multinational originator companies with leading ophthalmic franchises may benefit from prolonged market exclusivity as domestic generics face steeper development hurdles, though the guidelines also provide a clearer pathway for high-quality local entrants to compete on clinical evidence.
Forward-Looking Statement
Industry analysts expect the guidelines to trigger a wave of supplemental applications and new generic filings for eye drops in the fourth quarter of 2026, as manufacturers race to establish consistency evaluation portfolios ahead of anticipated delisting deadlines for non-compliant products. The CDE is likely to publish a dedicated reference preparations catalog for ophthalmic generics by year-end, enabling holders to select comparator products for equivalence studies. Companies with existing eye drop portfolios should audit their formulations against the new guidelines immediately, as the specialized eye drops provisions may require costly formulation redevelopment or additional clinical trials. The standards are expected to elevate overall quality in China’s ophthalmic generics sector, potentially opening export opportunities to regulated markets that recognize Chinese consistency evaluation data.-China Health Reform Pulse
Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/86f260be2272ece3d89e6dda2eaea22e